Detalhe da pesquisa
1.
Phosphotyrosine-based Phosphoproteomics for Target Identification and Drug Response Prediction in AML Cell Lines.
Mol Cell Proteomics
; 19(5): 884-899, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32102969
2.
Crizotinib sensitizes the erlotinib resistant HCC827GR5 cell line by influencing lysosomal function.
J Cell Physiol
; 235(11): 8085-8097, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31960422
3.
(Immuno)proteasomes as therapeutic target in acute leukemia.
Cancer Metastasis Rev
; 36(4): 599-615, 2017 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-29071527
4.
Exosomes Secreted by Apoptosis-Resistant Acute Myeloid Leukemia (AML) Blasts Harbor Regulatory Network Proteins Potentially Involved in Antagonism of Apoptosis.
Mol Cell Proteomics
; 15(4): 1281-98, 2016 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-26801919
5.
Antileukemic activity and mechanism of drug resistance to the marine Salinispora tropica proteasome inhibitor salinosporamide A (Marizomib).
Mol Pharmacol
; 86(1): 12-9, 2014 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-24737138
6.
Higher ratio immune versus constitutive proteasome level as novel indicator of sensitivity of pediatric acute leukemia cells to proteasome inhibitors.
Haematologica
; 98(12): 1896-904, 2013 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-24056819
7.
Statins markedly potentiate aminopeptidase inhibitor activity against (drug-resistant) human acute myeloid leukemia cells.
Cancer Drug Resist
; 6(3): 430-446, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37842233
8.
Fourth mRNA COVID-19 vaccination in immunocompromised patients with haematological malignancies (COBRA KAI): a cohort study.
EClinicalMedicine
; 61: 102040, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-37337616
9.
Quantitative analysis of mRNA-1273 COVID-19 vaccination response in immunocompromised adult hematology patients.
Blood Adv
; 6(5): 1537-1546, 2022 03 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35114690
10.
Immortalization of oral keratinocytes by functional inactivation of the p53 and pRb pathways.
Int J Cancer
; 128(7): 1596-605, 2011 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-20499310
11.
Pre-Clinical Evaluation of the Proteasome Inhibitor Ixazomib against Bortezomib-Resistant Leukemia Cells and Primary Acute Leukemia Cells.
Cells
; 10(3)2021 03 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-33802801
12.
Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab.
Clin Cancer Res
; 23(24): 7498-7511, 2017 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29025767
13.
Proteasome subunit expression analysis and chemosensitivity in relapsed paediatric acute leukaemia patients receiving bortezomib-containing chemotherapy.
J Hematol Oncol
; 9(1): 82, 2016 09 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-27599459
14.
Exocytosis of polyubiquitinated proteins in bortezomib-resistant leukemia cells: a role for MARCKS in acquired resistance to proteasome inhibitors.
Oncotarget
; 7(46): 74779-74796, 2016 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-27542283
15.
Interferon-γ-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines.
J Hematol Oncol
; 7: 7, 2014 Jan 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-24418325
16.
Anti-leukemic activity and mechanisms underlying resistance to the novel immunoproteasome inhibitor PR-924.
Biochem Pharmacol
; 89(1): 43-51, 2014 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-24552657
17.
Overcoming bortezomib resistance in human B cells by anti-CD20/rituximab-mediated complement-dependent cytotoxicity and epoxyketone-based irreversible proteasome inhibitors.
Exp Hematol Oncol
; 2(1): 2, 2013 Jan 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-23305345
18.
Proteasome-based mechanisms of intrinsic and acquired bortezomib resistance in non-small cell lung cancer.
Biochem Pharmacol
; 83(2): 207-17, 2012 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-22027222
19.
Cell sensitivity assays: the MTT assay.
Methods Mol Biol
; 731: 237-45, 2011.
Artigo
em Inglês
| MEDLINE | ID: mdl-21516412